Literature DB >> 1845391

Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection.

M Clerici1, C O Tacket, C S Via, D R Lucey, S C Muluk, R A Zajac, R N Boswell, J A Berzofsky, G M Shearer.   

Abstract

Healthy, human immunodeficiency virus seronegative (HIV-) volunteers were multiply immunized with a recombinant gp160 (rgp160) candidate acquired immunodeficiency syndrome (AIDS) vaccine. Peripheral blood lymphocytes from volunteers immunized with 40 micrograms or with 80 micrograms (two volunteers per group) of rgp160, as well as from control donors, were tested for T helper (Th) cell function either prior to immunization, 8 to 12 months after the third immunization, or 2 to 5 months after the fourth immunization. The Th cell functional tests included antigen-induced in vitro interleukin 2 (IL 2) production and proliferation in response to influenza A virus (FLU) and to four synthetic peptides of HIV gp120 and gp160, previously demonstrated to be recognized by T cells from HIV naturally infected patients. Our results demonstrate the following: (a) immunization of HIV- individuals with rgp160 results in IL 2 production and T cell proliferation in response to HIV determinants; (b) boosting with rgp160 enhances Th function; (c) HIV-specific Th function is up to 100-fold greater in the multiply immunized volunteers than that observed in asymptomatic, HIV-infected individuals; and (d) multiple immunization with rgp160 does not impair Th function to a non-HIV antigen such as influenza A virus. These results indicate that immunization of uninfected individuals with an HIV subunit vaccine results in much stronger Th cell immunity than does natural infection and suggests that vaccination against HIV may be possible.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845391     DOI: 10.1002/eji.1830210603

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

2.  Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.

Authors:  S Peifang; G L Pira; D Fenoglio; S Harris; M G Costa; V Venturino; V Dessì; G Layton; J Laman; J G Huisman
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

3.  Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.

Authors:  Said Aboud; Charlotta Nilsson; Katarina Karlén; Mary Marovich; Britta Wahren; Eric Sandström; Hans Gaines; Gunnel Biberfeld; Karina Godoy-Ramirez
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

4.  Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals.

Authors:  A Achour; F Bex; P Hermans; A Burny; D Zagury
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

5.  Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro.

Authors:  G Baier; G Baier-Bitterlich; D J Looney; A Altman
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

6.  Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus.

Authors:  M Clerici; T A Wynn; J A Berzofsky; S P Blatt; C W Hendrix; A Sher; R L Coffman; G M Shearer
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

7.  Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.

Authors:  Mariangela Garofalo; Monika Staniszewska; Stefano Salmaso; Paolo Caliceti; Katarzyna Wanda Pancer; Magdalena Wieczorek; Lukasz Kuryk
Journal:  Vaccines (Basel)       Date:  2020-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.